Celebrated American short-story writer and poet, Edgar Allan Poe, famously wrote, “Quoth the Raven ‘Nevermore.’”
At EpicentRx we “quoth” the dosing regimen of RRx-001 (nibrozetone) in the Phase 2b KEVLARx clinical trial as “4 Before and Then No More.”
Clearly no competition for Edgar Allan Poe are we. 😂
That said, this mnemonic succinctly describes how we administer RRx-001 (nibrozetone) 4 times, twice per week, in the 2 weeks prior to the start of cisplatin and intensity modulated radiotherapy (IMRT) for the treatment of locally advanced head and neck cancer.
Which is convenient to say the least – for healthcare providers and patients.
We can only dose this way because of the long effective half-life of RRx-001 (nibrozetone), whose antioxidant and anti-inflammatory effects are thought to exceed the pro-oxidant and pro-inflammatory effects of the 7-week course of cisplatin and IMRT.
We asked several oral mucositis experts or mavens around the country whether they wanted us to repeat our “4 Before…” mnemonic of which we are so fond.
Quoth the Mavens, “Nevermore.”